Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiajian Guishen Granules for Poor Ovarian Response
NCT06089395Phase 1Not yet recruiting
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Modality
- TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Jiajian Guishen Formulation in poor ovarian response (POR) (2 arms). Primary endpoint: Anti-Mullerian Hormone. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
Jiajian Guishen Formulation
03
Conditions
poor ovarian response (POR)
Beyond the preview
Go deeper on NCT06089395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089395.